We review current concepts regarding the genetic, unclear, and individuals with low or null concentrations of plasma lipoprotein(a) manifest no deficiency structural and metabolic features of lipoprotein(a), a major inherited cardiovascular pathogen. Although syndrome or disease. The integration of recent discoveries about the structure and metabolism of this lipoprotein(a) is almost completely confined to a subset of primates, the hedgehog produces a unique lipoprotein particle has allowed the formulation of some hypotheses concerning the evolutionary lipoprotein(a)-like complex, which appears to have evolved independently from that of humans. 
Summary
We review current concepts regarding the genetic, unclear, and individuals with low or null concentrations of plasma lipoprotein(a) manifest no deficiency structural and metabolic features of lipoprotein(a), a major inherited cardiovascular pathogen. Although syndrome or disease. The integration of recent discoveries about the structure and metabolism of this lipoprotein(a) is almost completely confined to a subset of primates, the hedgehog produces a unique lipoprotein particle has allowed the formulation of some hypotheses concerning the evolutionary lipoprotein(a)-like complex, which appears to have evolved independently from that of humans. The advantages of synthesizing lipoprotein(a)-like particles. physiological role of lipoprotein(a) in humans is still
Structure and metabolism of lipoprotein(a)
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein which is processed into the mature form and then secreted into the blood stream.7 Rapidly after secre-(LDL)-like particle formed by the association of the highly polymorphic glycosylated apolipoprotein(a) tion, free apo(a) binds to circulating LDLs to generate complete Lp(a) particles.8 The assembly of Lp(a) (apo(a)) with apolipoprotein B100 (apo B100), the classic protein moiety of LDL.1 In assembled Lp(a) occurs almost exclusively extracellularly, as no apo(a)-apoB100 complexes can be detected within lipoprotein particles, apo(a) is attached to apo B100 through a single disulphide link between apo B100 cells.7 From the composition and physicochemical properties of Lp(a-), the lipoprotein remnant derived Cys 3734 and apo(a) kringle IV type 9 Cys67;2 additional non-covalent interactions play accessory after dissociation of apo(a) from Lp(a) by chemical reduction, Lp(a) can be reasonably considered a roles in promoting, mediating and reinforcing the association between the apolipoproteins.3,4 Under genetically-determined variant of LDL, increased in density and size (Table 1) .9 Lp(a) belongs to the microscopic analysis of Lp(a) particles, apo(a) assumes a belt-like structure; both apo(a) ends are heterogeneous family of cholesterol-enriched lipoproteins: cholesterol, in either free or esterified form, attached at two distant sites to a spherical LDL. 5 Although apo(a) transcripts have recently been represents almost 40% of its total mass. The relative weight of phospholipids (17-24%) is comparable to found in adrenal glands, lungs, pituitary, brain and testes,6 circulating apo(a) is mainly synthesized by that of proteins (17-29%), whereas the triglyceride content is rather limited, usually below 9%.9-14 the liver as a precursor with lower molecular mass Almost 23% of the apo(a) mass is attributable to Nrelated genes, unlinked to the apo(a) gene cluster and O-glycosides, producing the remarkable electroand resident on chromosomes 2 and 4.22 negative potential of the Lp(a) lipoprotein particle.12
The apo(a) gene belongs to a puzzling gene family Aside from the structural homology to LDL, Lp(a) that includes several similar sequences encoding displays unique metabolic features. About 90% of prothrombin, tissue-type plasminogen activator Lp(a) concentration is under genetic regulation. The (t-PA), urokinase A-chain, plasminogen, coagulation greatest part of the variability in Lp(a) levels (over factor XII, macrophage stimulating factor, hepatocyte 40%) is accounted for by quantitative polymorphism growth factor and other proteins and polypeptides in the internal sequence of the apo(a) gene; qualitatof unclear function.23 Nucleotide analysis of human ive polymorphisms in the sequence of the promoter genes encoding these proteins reveals that sequences play only a minor role (from 10 to 14%).15 Despite of exons and relative boundaries differ only from 1 this genetic regulation, some metabolic abnormalities to 5%, and that the types of exon/intron junctions may have effects on Lp(a) levels in plasma.16, 17 and the positions of introns in the sequences are Among these, the acute-phase response, hormonal almost identical. These data suggest that the genes homeostasis, diabetes, liver and renal failure, and might have developed during recent primate evoludefects in the LDL-receptor gene have all been tion from a common ancestral component of the shown to influence the still enigmatic metabolism of kringle-related serine proteases, most likely plasminthis lipoprotein.
ogen, via duplication and exon shuffling.18,24 The apo(a) gene shares the highest homologies with the gene of the zymogen plasminogen; the sequence
The apo(a) gene cluster encoding for plasminogen kringle V domain is retained, whereas the plasminogen kringle IV domain The ability to synthesize apo(a) is confined to a encoding sequence exists in multiple variable tandem restricted group of primates; however, the insectivore repeats. In contrast, apo(a) lacks the sequences of hedgehog produces an apo(a)-like protein composed plasminogen preactive region and plasminogen krinof multiple tandem repeats of a plasminogen gle domains I through III. Despite the strong genetic kringle III homologous domain but lacking the prohomologies, a single point mutation in the sequence tease domain.18 Apo(a) sequence comparisons and of the protease domain deprives apo(a) of most of phylogenetic analysis indicate that human and plasminogen's enzymic properties. Sequencing of hedgehog genes evolved independently from differcloned human apo(a) complementary DNA revealed ent sequences, providing a novel model of 'converthat apo(a) contains 10 different kringle IV subtypes, gent' molecular evolution.19 designed as types 1-10. 25 The high quantitative The human apo(a) gene is located in a gene polymorphism in the sequence encoding the plasmincluster within 400 kb of genomic DNA on the ogen kingle IV type 2 domain explains the high telomeric region of chromosome 6 (6q26-27),20, 21 degree of individual allelic size polymorphism of the including the sequences encoding apo(a), plasminprotein as, to date, no fewer than 34 size alleles ogen and other two pseudogenes with highly have been identified in the apo(a) locus, encoding homologous untranslated 5∞ flanking regions. 22 as many detectable isoforms in plasma. [26] [27] The size Hybridization analysis and reverse transcriptase polyof the apo(a) particle usually determines its rate merase chain reaction have identified three additional homologues genes designated as plasminogenof hepatic synthesis and secretion; null alleles, producing virtually no detectable circulating Lp(a), released from activated or senescent neutrophils, enhances the binding of Lp(a) to endothelial cells by can be frequently observed. The molecular basis of these null alleles seems to be an in-frame 47-aminoapproximately four-fold and to smooth muscle cells by six-fold. 36 Although it is not yet clear whether acid deletion in the sequence of the protease domain that hinders the correct splicing of mRNA and Lp(a) particles are internalized directly or instead by prior extracellular degradation, the large amount of generates a defective protein, irregularly subjected to a sequence of intracellular rearrangements which cholesterol carried by the lipoprotein can easily be extracted and used at the site of its accumulation. are essential for processing and secretion of complete and functional particles.28 Among these, the trimming Lp(a) binds to several components of the vascular wall and of the sub-endothelial matrix;37 this binding of N-linked glucoses, which occurs after the folding of the protein into the endoplasmic reticulum, is is partially mediated by the lysine binding sites (LBS) of its apo(a) moiety. 35 High affinity bindings to thought to be a critical process. 29 Little is known about the two adjacent fibronectin, fibrinogen, glycosaminoglycans and proteoglycans were observed in the presence of apo(a)-related genes located on the apo(a) gene cluster on chromosome 6q26-27, called apo(a)-Ca2+ and Mg2+ ions; further weaker interactions were described with laminin and beta-2 glycoprotein related genes C and B, respectively. Although apo(a)-related gene B appears to be substantially I, but no binding was observed to von Willebrand factor, vitronectin or collagen type IV.37-39 silent, a 132-amino-acid human liver transcript composed of a secretion signal and a single kringle domain from the apo(a)-related gene C was recently The benefits of Lp(a) (hVSMCs) in culture by inhibiting the activation of transforming growth factor-b.41 These observations As nothing seems to happen casually in nature, we are unsurprising, considering that apo(a) belongs to should be able to identify at least one reasonable a family of growth factors evolved from a common explanation for the appearance of Lp(a) in humans ancestral kringle-containing serine protease, includand hedgehogs. There are several different human ing the hepatocyte growth factor/scatter factor proteins and polypeptides whose biological functions (HGF/SF), a potent effector in promoting growth, are yet unclear; however, it does not necessarily movement, and differentiation of epithelia and endomeans that they are useless. This might be particularly thelia, and the hepatocyte growth-factor-like/macrotrue for Lp(a).
phage-stimulating protein (HGF1/MSP), an effector of macrophage chemotaxis and phagocytosis.42
Lp(a) promotes tissue repair
A conceivable scenario is summarized in Figure 1 . As a vascular injury occurs, the acute-phase It now seems very likely that Lp(a) offered an evolutionary advantage to humans by promoting or response, concomitantly induced by the cellular release of several mediators, including IL-6, stimuaccelerating the healing of wounds and the repair of tissue injuries and vascular lesions. This hypothesis lates the hepatic synthesis of newly-formed apo(a) molecules, thereby producing complete circulating is supported by several lines of biological evidence.
Lp(a) behaves as an acute-phase reactant. The Lp(a) particles in the blood stream. Shortly afterwards, Lp(a) accumulates at the site of the vascular injury sequence of the apo(a) gene contains several interleukin 6 (IL-6)-responsive elements that enhance tranas it binds to cellular receptors at the surface of residual vascular cells, macrophages and platelets, scription of the gene.31 IL-6 generates a marked, dose-dependent enhancement of apo(a) mRNA synto the exposed sub-endothelial matrix and to immobilized fibrin. The large amount of apo(a) bound to thesis that leads to the accumulation of Lp(a) particles in hepatocyte culture,32 and several prospective clinthe fibrin surface and, to a lesser extent, to platelets and endothelial cells, inhibits the lysis of the clot. ical trials demonstrated significant rises in plasma Lp(a) after inducing different forms of acute phase At the same time, the growth-factor-like properties of Lp(a) promote vascular repair, and cell regeneraresponse in vivo. 33 Due to the additional presence of apo(a), Lp(a) tion is ensured by the large amount of cholesterol carried by the lipoprotein. In contrast to other can be recognized by a broad variety of receptors at the surface of endothelial cells, macrophages, cholesterol-rich lipoproteins, Lp(a) concentration is not substantially influenced by changes in dietary fibroblasts and platelets.34,35 Defensin, a peptide habits. Therefore, it is conceivable that, given the As most plasminogen-derived kringles have a different dietary habits of primates several million strong inhibitory effect on angiogenesis45,46 and years ago, and the much lower plasma levels of total apo(a) kringle domains are highly homologous to cholesterol and LDL-cholesterol, the amount of choplasminogen residues (77-100%),25 it is quite conlesterol carried by Lp(a) might have represented an ceivable that Lp(a) kringle fragments produced after important source of substrates for cell regeneration physiological degradation of whole particles in vivo47 and growth. On this basis, Lp(a) could have been an have similar properties in antagonizing or reducing essential component for tissue repair, whose primary growth and spread of cancers. However, the clinical functions might have been the delivery of large relationship between Lp(a) and cancer is still rather amount of cholesterol to peripheral cells and the obscure. The concentration of Lp(a) is commonly promotion of regeneration following events such as reported to be significantly increased in cancer injuries or inflammatory processes. Convincing suppatients as compared to healthy controls, irrespective port for this hypothesis was recently provided by of source and degree of malignancy of the tumour.48 Yano and colleagues, who described a markedly Taken together, this evidence might ascribe an positive staining for Lp(a) closer to the surface of the essential role to Lp(a) in the biological fight against fibrous cap, as well as in endothelial cells, and in malignancy. Among its various responses to cancer, the extracellular space of small vessels underlying the organism might generate a substantial rise in the fibrous cap of granulation tissues during wound Lp(a) concentrations, and the large content in kringle healing. 43 domains of apo(a) might then exert a powerful antineoplastic effect. Although this hypothesis sounds
Lp(a) inhibits cancer growth and spread very attractive, there are some serious difficulties. First, the recognized growth-factor-like functions of O'Reilly and colleagues recently demonstrated that Lp(a) on endothelial and smooth cells appear someangiostatin, a 38 kDa fragment generated by cancerwhat incompatible with an eventual inhibitory effect mediated proteolysis of plasminogen, including on angiogenesis; secondly, systemic administration plasminogen kringle domains I through IV, inhibits of intact kringle-containing proteins does not inhibit neovascularization of tumours and metastasis. 44, 45 neovascularization and growth of metastases and Furthermore, a recombinant form of plasminogen primary tumours46 and, to our knowledge, no study kringle V domain, sharing high sequence homology has yet investigated the hypothetical anti-neoplastic with the four kringles of angiostatin, inhibits endothelial cell migration.46 function of Lp(a) in vitro; finally, the current clinical observations require further support as they emerged effect on plasma Lp(a).52 Taken together, this evidence suggests that, although vitamin C might repressubstantially from longitudinal studies-no definitive prospective investigations are available at present. ent a powerful agent against heart disease, its biological relationship with Lp(a) needs further investigation.
Lp(a) is a surrogate for ascorbate
According to the classic 'unified theory' of former Nobel prize-winner Linus C. Pauling and Mathias Rath,
The pathogenicity of Lp(a)
human occlusive cardiovascular disease is a degenerative condition induced by chronic ascorbate (vitLp(a) and atherosclerosis amin C) deficiency, in which the large extracellular deposition of Lp(a) represents a powerful biological Shortly after its discovery, raised levels of Lp(a) were repeatedly associated with an increased incidence defensive mechanism49,50 Thereby, Lp(a) is regarded as a surrogate for ascorbate. Some evidence has of a variety of cardiovascular diseases, including silent coronary artery disease (CAD), acute myocardbeen found to support this hypothesis.
First, the original identification of Lp(a)-ial infarction (AMI), asymptomatic carotid atherosclerosis, stroke, and peripheral artery occlusive immunoreactive material was restricted to primates and to the guinea pig, both of which have lost their disease (PAOD).53,54 Additionally, elevated Lp(a) levels in plasma were shown to be strong indicators ability to synthesize vitamin C de novo. 49 On this basis, Lp(a) might have replaced ascorbate in most of vasculogenic erectile dysfunction55 and retinal artery occlusion.56 Usually, the Lp(a) familial excess species as a result of the evolutionary process.50 The biological capability to synthesize ascorbate was represents the most frequent lipoprotein abnormality observed in patients with premature myocardial probably lost in primates and guinea pigs after the introduction of substantial changes in dietary habits, infarction.57 Although retrospective case-control studies basically agreed in ascribing a substantial role to presumably towards foods containing larger amount of vitamin C.
Lp(a) in the pathogenesis of cardiovascular diseases, this association emerged less clearly from prospective Secondly, adequate amounts of ascorbate (40 mg/kg body weight/day) prevent the accumulastudies. In fact, whereas some prospective studies reported raised levels of Lp(a) in patients tion of Lp(a) in the arterial wall and the consecutive development of atherosclerosis in animal models. 51 with CAD,58-64 others failed to demonstrate such an association.65-67 Several explanations were proposed Thirdly, Lp(a) might share some basic properties with ascorbate. It was suggested that Lp(a) contributes for this apparent contradiction. Briefly, due to the intrinsic genetic, structural and metabolic complexity to the strengthening of the extracellular matrix, particularly in circumstances of ascorbate deficiency.
of Lp(a), reliable conclusions drawn from the analysis of results of Lp(a) investigations require the uncondiAt lower ascorbate concentrations, the instability of the extracellular matrix resulting from impaired syntional application of rigorous and standardized protocols.53-54,68 Furthermore, emerging evidence thesis of collagen and elastin might be temporarily improved by a large deposition of Lp(a). Moreover, demonstrates that the atherogenic properties of Lp(a) are intimately linked to those of LDL;69 accordingly, Lp(a) may delay lipid peroxidation.49,50 Finally, elevated concentrations of plasma Lp(a) are usually the cardiovascular potential of Lp(a) appears more substantial in hypercholesterolaemic subjects,70 and associated with cardiovascular diseases, where the overall incidence could be decreased by dietary substantial reductions in LDL-cholesterol (LDL-C) attenuate the clinical threat of persistent elevations supplementation with ascorbate.50 Similar observations have also been made in cancer and diabetes of Lp(a).71 From this perspective, although common treatments for lowering LDL-C usually have no effect patients.
To our knowledge, no other reliable clinical or on Lp(a), the identification of patients with raised concentrations of both Lp(a) and LDL-C might be biological evidence regarding strong relationships between Lp(a) and ascorbate in humans has been crucial in clinical management, basically promoting a more aggressive treatment of other concurrent published after the studies of Rath and Pauling. Additionally, further studies failed to demonstrate modifiable risk factors. Some doubts remain about the atherogenic potential of Lp(a) in Black populaeither Lp(a)-immunoreactive material in plasma or apo(a) mRNA in the liver of the guinea pig, suggesting tions. In fact, although the concentration of Lp(a) in African Americans is from two-to four-fold higher that the material originally identified by Rath and Pauling might be cross-reacting proteins or polypepthan in matched Caucasian Americans, the overall atherogenic risk in the two racial groups appears tides.19 Finally, high-dose ascorbate supplementation in patients with premature coronary heart disease comparable. Several lines of biological evidence can be used did not produce any clinically important lowering to explain the role of Lp(a) in the genesis, developexplain the anti-fibrinolytic potential of Lp(a).99 A considerable part of the anti-fibrinolytic properties ment and complication of atherosclerotic lesions. Lp(a) immunoreactive material can be selectively of apo(a) seems to reside in its molecular similiarity to plasminogen.25 Lp(a) inhibits plasminogen binding demonstrated in the vascular wall of several arterial vessels, including the aorta72, and coronary,73 cereband activation at the surface of stabilized fibrin, endothelial cells and platelets in a dose-dependent ral74 and peripheral arteries75; in those sites, the relative amount of apo(a) deposition is significantly fashion, and the inhibitory effect on plasmin generation in vitro may be related to the size of the apo(a) related to the extent of atherosclerosis.74 Accordingly, large amounts of Lp(a) can be demonstrated in particle, as smaller isoforms produce more pronounced inhibition.100 Recently, Harpel and colgrowing atherosclerotic plaques and vein grafts.76 In growing atherosclerotic lesions, the accumulation of leagues demonstrated that the strength of the binding between apo(a) and stabilized fibrin can be increased apo(a) in degraded, free and intact (but oxidized) forms appears to be preferential to that of other by incubation with homocysteine and other sulfhydryl compounds, such as cysteine, glutathione and apolipoproteins.77 The cellular uptake and degradation of Lp(a) follows several pathways, as Lp Only few animal species have developed the ability to synthesize Lp(a) along their evolution: a subset of
Lp(a) and thrombosis
primates and the insectivore hedgehog. According to a recent theory, the phylogenetic evolution of the Raised Lp(a) concentrations have been observed in patients with several thrombotic occlusive disorders hedgehog apo(a)-like gene can be dated back to about 80m years ago, whereas the appearance of such as pulmonary embolism,92 central retinal vein occlusion93 and interference in placental circulation apo(a) in primates occurred much more recently, probably during the recent evolution of these causing fetal growth retardation.94,95 Lp(a) levels are strong predictors of both occlusive events following species.18 Additionally, the hedgehog apo(a)-like gene shows substantial distinctive features in terms vascular and endovascular surgical procedures96 and development of thrombotic episodes in patients with of structure and evolutionary history from human apo(a); in fact the former gene encodes a protein severe rheumatological diseases.97 Finally, the convergence of the strong atherogenic and thrombotic composed of highly repeated copies of a plasminogen kringle III-like domain but is completely lacking potentials of Lp(a) plays a pivotal role in the complication of atherosclerotic lesions, as usually the sequences encoding the plasminogen preactivation peptide, for plasminogen kringles I, II, IV and V occurs after rupture or ulceration of atherosclerotic plaques. 98 and for the protease domain.18 It is well known that the restricted availability of biological substrates and Several plausible mechanisms were proposed to 5. Xu S. Apolipoprotein(a) binds to low-density lipoprotein at the necessary adaptation to particular habits or two distant sites in lipoprotein(a). Biochemistry 1998; habitats has produced widespread phenomenon of its ancestral useful properties. 
